Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Switch Biotech AG was a German biotechnology company founded in 1997, specializing in functional genomics for dermatology and wound healing. The company utilized its proprietary DADA (Digital Analysis of cDNA Abundance) platform to identify and validate gene targets involved in the molecular pathophysiology of skin diseases. Switch Biotech established significant research and development partnerships, notably with Leo Pharma and 4SC, to discover and screen novel therapies for conditions such as psoriasis and chronic wounds. Despite its innovative technology and early-stage pipeline, the company filed for insolvency in 2004 and is currently defunct.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Switch Biotech Association.